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CARDIOVASCULAR DISORDERS – Clinical Outcomes Studies
PCV1
COStO-EfECtIVIDAD DE Un PROgRAmA DE nEfROPROtECCIOn En UnA 
COhORtE DE 17.000 PACIEntES COn EnfERmEDAD REnAL CROnICA 
AfILIADOS A UnA ASEgURADORA En SALUD En COLOmbIA
Guarin NE1, Arevalo HO1, Moreno JA1, Diaz JA2, Muñoz-Galindo IM1
1Salud Total EPS, Bogotá D.C., Colombia, 2Universidad Nacional de Colombia, Bogotá D.C., 
Colombia
La enfermedad renal crónica (ERC) es una condición de salud pública en aumento 
en Colombia y en el mundo. La intervención temprana de los factores de riesgo dis-
minuye su impacto en la morbilidad, mortalidad y costos de atención.ObjectivOs: 
Evaluar la costo-efectividad de un programa de nefroprotección en una cohorte de 
pacientes con ERC, hipertensión arterial (HTA) y/o diabetes mellitus tipo II (DM), 
afiliados a una aseguradora en salud en Colombia. MetOdOlOgíAs: Se construyó 
un modelo de Markov en MS Excel ® para representar la historia natural de la ERC 
considerando 4 estadios de la enfermedad según su progresión, comparando tres 
alternativas de intervención: atención regular de usuarios sin programa (alternativa 
A), programa de nefroprotección inicial (alternativa B) y programa de nefroprotec-
ción avanzado (alternativa C). Los costos directos fueron incluidos, de acuerdo con 
la información disponible en la aseguradora. La medida de resultado fueron Años 
de vida ajustados por calidad (AVAC) tomados de la literatura. Las probabilidades 
de transición se calcularon a partir del seguimiento de 16.992 pacientes con diag-
nóstico de ERC, HTA y/o DM, mayores de 18 años de edad, en 16 ciudades del país, 
durante los años 2010 a 2013. El horizonte temporal fue la vida. La perspectiva fue 
del tercer pagador. Se realizaron análisis de sensibilidad determinísticos y proba-
bilísticos. ResultAdOs: La alternativa B mostró un comportamiento dominado. 
El análisis de costo-efectividad entre la alternativa A y C muestra un ICER de USD $ 
4.826,51 por AVAC a favor de C. cOnclusiOnes: Dada la disposición a pagar de 1 
PIB per cápita para el país, el programa de nefroprotección avanzado es una opción 
muy costo-efectiva. Esta evaluación puede ayudar a los tomadores de decisiones 
a mejorar la asignación de recursos en países en vías de desarrollo al estimular la 
implementación de estrategias preventivas en patologías crónicas.
PCV2
EffECtIVEnESS Of thE St2 fOR PROgnOSIS In hEARt fAILURE: SyStEmAtIC 
REVIEwS
Kim S
National Evidence-based Collaborating Agency, Seoul, South Korea
Objectives: ST2 reflects activity of the cardioprotective signal and is a prognostic 
marker in heart failure. The aim is to assess the effectiveness of the ST2 for deter-
mination of the prognosis of patient with heart failure. MethOds: We searched the 
8 Korean databases and overseas databases including Ovid-MEDLINE, Ovid-EMBASE 
and Cochrane Library. A total 365 studies were searched through search strategy and 
total of 19 studies were included in the final assessment by the selection criteria. 
Each of the stages from literature search to application of selection standards and 
extraction of data were carried out independently by 2 researchers. We used tools 
of Scottish Intercollegiate Guidelines Networks(SIGN) for assessment of the qual-
ity of literature. Results: The effectiveness of the ST2 was assessed by means of 
association with prognosis(risk ratio(RR) or odds ratio(OR), accuracy of forecasting 
of the prognosis, stratification of risk), correlation with the comparative test and 
relevance with clinical symptoms. The RR or OR of the death arising from ST2 was 
1.01~4.56, the RR of hospitalization was 1.054~2.4. On the other hand, RR of hospi-
talization of BNP was 1.15~2.0, the RR or OR of death arising from NT pro-BNP was 
0.19~1.241. The sensitivity/specificity of the test was respectively 64~87%/51~82% 
and AUC values were 0.689~0.84. The stratification of risk (NRI values) on the death 
rate were reported to be significant at 9.4 and 9.9 in the 2 papers, respectively, the 
other 1 paper reported stratification of risk of the death rate of 0.049 and stratifica-
tion of risk of hospitalization rate of 0.0638. The correlation coefficients with BNP 
was 0.16~0.409 and with NT pro-BNP was 0.28~0.523. The correlation coefficient with 
the peak VO2was 0.30 and with 6-minute walk distance was 0.22. cOnclusiOns: 
The ST2 is effective in determining the prognosis of patients with heart failure and 
useful in treating heart failure.
PCV3
An OPEn LAbEL, OnE ARm StUDy tO EVALUAtE thE EffICACy AnD SAfEty 
Of CEREbROLySIn In PAtIEntS wIth ACUtE SEVERE ISChEmIC StROkE In 
mExICO
Martinez Sánchez BR1, Hernández Hernandez JJ1, Franco Del Águila DI1, Gryzbowski 
Gainza E2, Paz Ballesteros WC2, Herrera Rojas J2, Peniche Otero G2, Marroquín Y3, 
Zambrano Velarde LE1
1Cruz Verde, Guadalajara, Mexico, 2Information Technology Squad, SA de CV, Distrito Federal, 
Mexico, 3EVER Pharma México, S.A. de C.V, Distrito Federal, Mexico
Objectives: We aim to evaluate the efficacy and safety of cerebrolysin in Mexican 
patients with acute severe ischemic stroke (ASIS) and to describe their demo-
graphic and clinical characteristics along with their comorbidities and adverse 
events. MethOds: Open label, one arm, and dose decreasing exploratory study in 
30 consecutive patients from “Unidad Hospitalaria Cruz Verde Dr. Delgadillo Araujo” 
with ASIS starting within 48 hours from the onset of stroke; they received 50 ml of 
intravenous cerebrolysin daily for 10 days followed by 10 days of 30 ml. All patients 
underwent CT scan and were examined using the National Institutes of Health 
Stroke Scale (NIHSS) score and Modified Rankin Scale (≥ to 12 and ≥ 3, respectively) 
score at baseline as well as on day 15 after hospital discharged. Difference between 
measures was evaluated with paired Student’s t statistic. Results: The patients 
mean age was 60.26 ± 11.2 years, 16 (53%) were male and a majority were between 
50-70 years (60%). 19 patients reported at least one physical comorbidity (63.3%), 
the most frequently reported comorbidities were hypertension, diabetes mellitus 
and atrial fibrillation (n= 10, 33%; n= 9, 30%; n= 1, 3% respectively). Pretreatment 
mean score on the NIHSS scale was 20.4, SD 3.9, 95 CI [18.9 - 21.82]; mean Modified 
the approach of the cheapest drug in the market, only three regimens are cov-
ered by the APAC: cisplatin+docetaxel (574BRL~179USD), carboplatin+docetaxel 
(1,002BRL~313USD) and carboplatin+paclitaxel (984BRL~307USD). In addition, 
with the exception of target therapies, all regimens are recommended for 21 
days, being two months of APAC correspondent to 3 cycles. Considering this 
time mismatch, only cisplatin+docetaxel fits the APAC. cOnclusiOns: Our 
analysis indicated that patients may not have access to recommended treat-
ment because the reimbursement system is not updated to the advent of new 
technologies.
PCn65
A PhARmACOECOnOmIC AnALySIS Of COStS fROm thE tUmOR bAnk Of thE 
InStItUtO nACIOnAL DE CAnCEROLOgIA mExICO
Báez-Revueltas FB, Ruiz-Godoy LM
Instituto Nacional de Cancerología, Mexico City, Mexico
Objectives: To estimate the budgetary impact of the samples produced by the 
Tumor Bank of the ‘Instituto Nacional de Cancerología’ of Mexico in order to 
set a recuperation fee for the samples that provides from the perspective of the 
Health Sector of Mexico. MethOds: The study was an observational, retrospec-
tive review of the direct medical costs (CDMs) of each of the processes involved 
in the cryopreservation of samples collected at the tumor bank, on a per sample 
basis. Including materials, laboratory tests, personnel and administration costs. 
Materials and labor costs were determined from hospital information. Costs were 
determined depending on the sample: plasma, tissue and biopsy and costs were 
calculated depending on the process required to preserve each kind of sample. 
Sensitivity analysis was performed using bootstrap. Results: Recuperation 
costs range from 130 to 155 USD. These costs were considered on a five-year time 
frame for the maintenance per sample, which is the average time a sample is 
kept in the bank. cOnclusiOns: This cost analysis, perceive an adequate recu-
peration fee per sample needed in order to guarantee the correct development of 
the bank.
PCn66
SObREVIDA DE CInCO AnOS E fAtORES ASSOCIADOS AO CânCER DE bOCA 
PARA PACIEntES Em tRAtAmEntO OnCOL”gICO AmbULAtORIAL PELO 
SIStEmA ÚnICO DE SAÚDE, bRASIL
Cherchiglia ML1, Bonfante GM1, Machado CJ1, Souza PE2, Andrade EI1, Acurcio FD 3
1Federal University of Minas Gerais, Belo Horizonte, Brazil, 2Pontifícia Universidade Católica de 
Minas Gerais, Belo Horizonte, Brazil, 3College of Pharmacy, Federal University of Minas Gerais, 
Belo Horizonte, Brazil
ObjetivOs: Analisar a sobrevida específica de cinco anos e fatores associados para 
câncer de boca no Brasil MétOdOs: Trata-se de coorte retrospectiva, cuja fonte de 
dados foi a Base Onco, que realizou o relacionamento probabilístico-determinístico 
de todos os registros de autorização para radioterapia e/ou quimioterapia pelo 
Sistema Único de Saúde, entre 2000 e 2006, gerando-se cadastro único para cada 
paciente. O evento de interesse foi o tempo decorrido entre o diagnóstico do câncer 
de boca e o óbito por este câncer. O Modelo de Regressão de Cox foi utilizado para 
avaliar os fatores individuais associados ao evento de interesse. ResultAdOs: O 
presente estudo incluiu os pacientes diagnosticados entre 2002 e 2003 com câncer 
de boca, exceto lábio, e idade entre 19 e 100 anos (N = 6.180). A taxa de sobre-
vida específica em cinco anos foi de 60%. Foram associados à menor sobrevida 
específica: ter idade > 40 anos; apresentar estádio III ou IV; localização em língua, 
assoalho de boca e base de língua; não realizar tratamento cirúrgico, realizar 
somente quimioterapia ou radioterapia e quimioterapia e residir em determi-
nados estados do Brasil. cOnclusões: Os resultados reforçam a necessidade 
de incluir a avaliação das disparidades dos territórios de planejamento como 
possibilidade para incrementar as ações de saúde e melhorar os indicadores de 
sobrevida
PCn67
ChAngE In thE DEmOgRAPhIC PROfILE AnD ImPACt In thE mORtALIty Of 
mELAnOmA AnD LUng CAnCER In PUERtO RICO 2000-2010
Orengo JC1, Arbalaez F1, Lutz M2, Baker-Ivey T3, Marques-Goyco C1, Monsanto H4,  
Green VS5
1MSD Caribbean Region, Carolina, PR, PR, 2MSD Caribbean Region, San José, Costa Rica, 3MSD 
Caribbean Region, Kingston, Jamaica, 4MSD Latin America Region, Carolina, PR,PR, 5Ponce Health 
Sciences University, Ponce, PR,PR
Objectives: The demographic profile of Puerto Rico is changing; according the 
2000 and 2010 Census of the Population, Puerto Rico has 3810,605 and 3,722,133 
inhabitants, respectively. In this period the population of 65 years or older 
increased from 11.2% to 15%; the median age increased from 33.8 years in 2004 
to 37.0 years in 2010. The extent to which these population changes affect cancer 
mortality is not known. The objective was: to assess the impact of changes in the 
demographic profile of Puerto Rico from 2000 until 2010 on melanoma and lung 
cancer mortality. MethOds: The method of Bashir and Esteve (2000) was applied 
in this study. The baseline group was the year 2000 and the comparison group the 
year 2010. The mortality of these groups was assessed according: population size, 
structure of the population and risk. The population was age adjusted. The mortal-
ity of melanoma and lung cancer is from the National Centre of Health Statistics 
and the population from the Census Bureau (2000, 2010). Results: The net change 
in melanoma mortality was one death; there was an increase of 6 deaths due to 
change in the structure and a decrease of 5 deaths due to change in the size (1) 
and due to risk (4). Net change in lung mortality was 22 deaths; an increase of 
166 deaths due to change in the structure and a decrease of 144 deaths, 14 due to 
change in the size and 130 due to risk. cOnclusiOns: Melanoma and lung can-
cer mortality in Puerto Rico has been affected by the change in the demographic 
profile, resulting in an increase in the number of deaths for these two types of 
cancer. The scope of cancer health services should be evaluated in light of this 
demographic change.
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were conducted in South America (92%), particularly in Brazil (64%). The mean age 
was 60 ± 9 years and the mean ejection fraction was 36 ± 9%. Most studies evalu-
ated more than one etiology (79%) but the etiology more studies exclusively was 
Chagas disease (13%). The incidence of HF ranged from 199 to 557 cases per 100,000 
person-years and the pooled prevalence was 1%, being higher in older populations. 
Hospitalization rates in patients with HF ranged from 28 to 31% at different time 
points, and the median length of stay was 7.0 days. In-hospital mortality was 11.7%, 
being higher in patients with worse ejection fraction, with ischemic and with Chagas 
disease. Mortality at one year was 24.52% (95%CI 19.42 to 30.02). cOnclusiOns: 
This SR of HF in Latin America, could help decision-makers to design better preven-
tive strategies, and guide effective patient-centered care.
CARDIOVASCULAR DISORDERS – Cost Studies
PCV7
bUDgEt ImPACt AnALySIS Of thE USE Of ALtEPLASE In thE tREAtmEnt Of 
ACUtE ISChAEmIC StROkE In mExICO
Huicochea-Bartelt JL1, Palacios E2, Zapata L2, Herran S1
1Boehringer Ingelheim, Distrito Federal, Mexico, 2Guia Mark, Distrito Federal, Mexico
Objectives: To estimate the economic impact of the use of alteplase versus best 
supportive care (BSC) in patients with acute ischemic stroke in Mexico. MethOds: 
A decision tree cost-effectiveness (CE) model assessed the treatment related cost for 
Alteplase and BSC related to two mayor disease branches: with or without intrac-
ranial hemorrhage. Terminal nodes in each arm included death, independent- or 
dependent survival. Published results of head to head clinical trials efficacy inputs 
populated the model. Treatment algorithm was obtained from the local governmen-
tal guide. Public institutional direct medical costs (2014 purchases and price tabula-
tors) where retrieved to adopt the national health system perspective. Governmental 
databases and 2014 purchases provided the epidemiology inputs. A five year fore-
cast estimated the budget impact of the use of alteplase versus BSC. Results: 
7,976 patients yearly were calculated to require medical attention due to an acute 
ischaemic stroke in Mexico. Mean saving per patient in the alteplase versus BSC 
arm was estimated to be US$67,142.76 at the CE model. 16% versus 12% positive 
response to treatment was seen at alteplase and BSC arms respectively. Starting 
at a 4% Market share level, and assuming an increasing share at a 1% rate per year, 
potential savings for new cases at year five (8% share) were estimated to be as high 
as US$35,342,527.00. cOnclusiOns: At a better response rate with lower costs of 
treatment, alteplase was estimated to be a cost-saving therapy versus BSC in a CE 
model. In a five year budget impact analysis, this novel alternative showed to bring 
potential savings in the public Mexican institutional context versus BSC. The savings 
proportionally increase with a higher levels of patients treated and market share.
PCV8
bUDgEt ImPACt AnALySIS Of thE USE Of tEnECtEPLASE In thE tREAtmEnt 
Of ACUtE myOCARDIAL InfARCtIOn In mExICO
Huicochea-Bartelt JL1, Palacios E2, Zapata L2, Herran S1
1Boehringer Ingelheim, Distrito Federal, Mexico, 2Guia Mark, Distrito Federal, Mexico
Objectives: To estimate the economic impact of the use of tenecteplase versus 
streptokinase in patients with acute myocardial infarction (AMI). MethOds: A 
decision tree cost-effectiveness (CE) model assessed the treatment related cost 
for tenecteplase and streptokinase related to two mayor disease branches: with or 
without acute reperfusion therapy. In the reperfusion arm, terminal nodes included 
none or one or more complications; those without therapy could only survive or 
die. Complications comprised death, reinfarction, cardiac failure, cerebral infarc-
tion, minor and mayor bleedings and intracranial hemorrhage. Published results 
of head to head clinical trials or indirect comparisons efficacy inputs populated 
the model. Treatment algorithm was obtained from the local governmental guide. 
Public institutional direct medical costs (2014 purchases and price tabulators) where 
retrieved to adopt the national health system perspective. Governmental databases 
and 2014 purchases provided the epidemiology inputs. A five year forecast esti-
mated the budget impact of the use of tenecteplase versus streptokinase. Results: 
20,002 patients yearly were calculated to require medical attention due to an AMI in 
Mexico. Mean saving per patient in the tenecteplase versus the streptokinase arm 
was estimated to be US$1,920.00 at the CE model. 98% versus 93% positive response 
to treatment was seen at tenecteplase and streptokinase arms respectively. Starting 
at a 3% Market share level, and assuming an increasing share at a 3% rate per year, 
potential savings for new cases at year five (15% share) were estimated to be as high 
as US$16,371,461.00. cOnclusiOns: At a better response rate with lower costs of 
treatment, tenecteplase was estimated to be a cost-saving therapy versus strepto-
kinase in a CE model. In a five year budget impact analysis, this novel alternative 
showed to bring potential savings in the public Mexican institutional context ver-
sus streptokinase. The savings proportionally increase with a higher market share.
PCV9
ImPACtO ORçAmEntáRIO DO EVEROLImO, SIROLImO E tACROLImO PARA 
ImUnOSSUPRESSãO Em tRAnSPLAntADOS CARDíACOS nO SIStEmA PÚbLICO 
DE SAÚDE DO bRASIL
Schneiders RE, Bastos EA, Domingues PH, Xavier LC, Reis FC, Alexandre RF,  
Nascimento Junior JM
Brazilian Ministry of Health, Brasília, Brazil
ObjetivOs: Analisar o impacto orçamentário da do everolimo, sirolimo e tac-
rolimo para transplantados cardíacos no Sistema Público de Saúde do Brasil 
(SUS). MétOdOs: Para estimar a população que realizou transplante cardíaco no 
Brasil passível de utilizar esses medicamentos, desenhou-se coorte hipotética a 
partir do número de transplantes de coração no Brasil entre 1999 e 2013, obtido por 
meio do Sistema de Informações do SUS, e da taxa anual de sobrevida ao longo de 
15 anos, extraída de estudo de coorte multicêntrico internacional. Considerando 
que os medicamentos em análise estão disponíveis no SUS para transplantados 
Rankin Scale (mRs) was 3.8 , SD 0.8, 95 CI [3.4 - 4.1 ]. At day 15 follow-up NIHSS, 
was 11; SD 4.5; 95 CI [9.3 - 12.8 ]; mean mRs score was 1.9, SD 0.7, 95 CI [1.7 - 2.2 ], 
(p = 0.000 and 0.000 respectively).Only one patient report nightmares as adverse 
event. cOnclusiOns: The current study demonstrate that cerebrolysin treatment 
improves functional outcome safely in Mexican patients with ASIS. Future double-
blind studies with larger sample sizes will further help to explore causal benefits 
of this drug in stroke outcome.
PCV4
A PhySICIAn-CEntERED IntERVEntIOn tO ImPROVE COntROL Of bLOOD 
PRESSURE: SyStEmAtIC REVIEw AnD mEtA-AnALySIS
Lima KM1, Ribeiro RA1, Ziegelmann P2, Leal L1, Schmidt F3, Polanczyk CA1
1Hospital Moinhos de Vento, Porto Alegre, Brazil, 2, Universidade Federal do Rio Grande do Sul, 
Porto Alegre, Brazil, 3Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
Objectives: To review trials of physician-centered interventions to reducing sys-
tolic blood pressure (SBP) and diastolic blood pressure (DBP). MethOds: Systematic 
review and meta-analysis. We searched MEDLINE, EMBASE and Cochrane Central for 
all-language articles up to September 2014. We included randomized controlled trial 
(RCT) of physician-centered interventions for hypertension compared with usual 
care or minimal intervention in primary care patients. Data were pooled using a 
random effect meta-analysis model. The effect were expressed as the weighted 
mean difference (WMD). Results: Twenty-five trials of 7595 citation were included. 
Seventeen studies were cluster RCT, one trial was factorial and cluster trial. The 
remaining seven studies were randomized at individual patient level; five of them 
used a two-by-two factorial design. Two studies did not report any estimates of vari-
ance. Overall, 23 trials (43.489 participants) was contribute to the meta-analysis. The 
physician-centered intervention were categorized as computer decision support (6 
trials), stepped treatment algorithm (6), Medical Education (4), Audit and feedback 
(3) and Multifaceted (4). Methodological quality of included studies was rather low. 
Only interventions that the main focus were stepped treatment algorithm showed 
significant reductions in blood pressure: weighted mean difference, systolic - 4.2 
mmHg; 95% confidence interval -5.3 to -3.2; I², 80.1% and diastolic -1.6 mmHg; 95% 
confidence interval -2.8 to -0.49; I². 93.4%. For the remaining five categories did not 
show to reducing blood pressure. Subgroup analyses by study design explained 
considerable heterogeneity in stepped treatment algorithm effect. cOnclusiOns: 
Physician-centered interventions based in stepped treatment algorithm showed 
significantly reductions of systolic and diastolic blood pressure. The magnitude of 
reduction in blood pressure is likely to prevent stroke and death in patients.
PCV5
AntIPSyChOtIC ExPOSURE AnD RISk Of StROkE: A SyStEmAtIC REVIEw 
AnD mEtA-AnALySIS Of ObSERVAtIOnAL StUDIES
Hsu W1, Esmaily-Fard A2, Lee C3
1National Taiwan University Hospital, Taipei City, Taiwan, 2The University of Texas MD Anderson 
Cancer Center, Houston, TX, USA, 3National Taiwan University Hospital, Yunlin Branch, Douliou, 
Taiwan
bAckgROund: Use of antipsychotic medications has been associated with 
increased risk of cerebrovascular events; however, this association remains ques-
tionable given conflicting evidence in the literature. Objectives: We conducted 
a systematic review and meta-analysis to determine the risk of stroke with the 
use of antipsychotic medications. MethOds: All articles published between 
1970 and February 2015 were identified by comprehensively searching PubMed, 
MEDLINE and EMBASE without language restrictions. Observational studies com-
paring stroke outcomes in antipsychotic patients with non-users were selected. 
Two authors independently extracted study characteristics and indicators of study 
quality. Newcastle-Ottawa Scale was adopted to assess risk of bias. Pooled odd 
ratios (ORs) and heterogeneity (I2) were estimated on the basis of random effects 
models. Results: We identified 22 potentially relevant studies from 1,171 citations. 
Of these, 9 studies (3 cohort, 5 case–control and 1 case-case-time-control) with a 
total of 155,789 subjects and 10,203 cases of stroke were eligible for final analysis. 
Use of antipsychotics was associated with a significantly higher risk of developing 
stroke [OR 1.57, 95% confidence interval (CI) 1.29-1.98, I2 = 92.4%]. The pooled OR 
for stroke was 1.58 [95% CI 1.01-2.49, I2 = 68.4%] with exposure to conventional 
antipsychotics and 1.06 [95% CI 0.59-1.89, I2 = 56.2%] with exposure to atypical 
antipsychotics. Subgroup analysis of conventional antipsychotics showed elderly 
patients over 64 years old were at lower risk for stroke [OR 1.37, 95% CI 0.87-2.17, I2 
= 64.5%]. Due to limited data on individual agents, only Risperidone was evaluated 
in the subgroup analysis of atypical antipsychotics. Risperidone users were less 
likely to develop stroke than non-users of antipsychotics [OR 0.63, 95% CI 0.33-1.17, 
I2 = 55.2%]. cOnclusiOns: Exposure to conventional antipsychotic was associated 
with a significant increase in stroke risk. Nonetheless, use of atypical antipsychotics 
revealed lower risk of stroke. Given heterogeneity among eligible studies, additional 
research is needed.
PCV6
bURDEn Of hEARt fAILURE In LAtIn AmERICA: A SyStEmAtIC REVIEw AnD 
mEtA-AnALySIS
Ciapponi A, Bardach A, Calderón M, Alcaraz A, Matta MG, Chaparro M, Soto N
Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina
Objectives: Heart failure (HF) is a common clinical syndrome representing the 
end-stage of several cardiac diseases. Our objective was to estimate the burden of 
heart failure in Latin America. MethOds: A systematic review and meta-analysis 
was performed. We searched in MEDLINE, EMBASE, LILACS, and CENTRAL from 
January 1994 to June 2014. We included non-comparative data from experimental 
and observational studies. No language restriction was imposed. We included stud-
ies with samples of at least 50 participants of 18 years of age or older with HF. The 
outcomes analyzed were incidence, prevalence, hospitalization rates and case fatal-
ity ratios of HF at different time points, length of stay and mortality. Results: The 
search retrieved 4792 references of which 143 studies were finally included. Most 
